Healthcare and Life Science
Call for glaucoma classification tool to be used nationally
Glaucoma is the most frequent cause of irreversible blindness but up to 40 per cent of patients could be missing out on crucial social support, warn Cambridge experts who hope their free technology will be embraced by clinicians nationally. ...
New £4.5million project to boost NHS staffing
Five-year scheme will be led in the East of England by experts from Anglia Ruskin. ...
EFEC explores UK-China Life Sciences Synergies at VBEF 2025
At Excellence First Enterprise Consultancy (EFEC), we have dedicated 19 years to forging successful UK-China partnerships, now connecting UK life sciences organisations with opportunities in China and preparing Chinese firms for success in the UK, growing together through shared innovat...
Senior nurse to bring vast experience to ARU role
Ruth May, England’s former Chief Nursing Officer, joins Anglia Ruskin University. ...
Labour boost for GP surgeries in Cambridge
Cambridge patients are set to benefit from thousands more GP appointments as Labour delivers a major cash boost to local surgeries. ...
China at Now - An EFEC insight for the UK life sciences community
China’s life sciences sector is undergoing a profound transformation, driven by rapid innovation, deepening global integration, and significant advancements in biopharmaceuticals and medical devices. ...
Genetic ancestry and parental smoking linked to new genetic changes in children
Ancestry and lifestyle choices of parents may affect the rate and type of new genetic changes that arise in their children, new research has found. ...
Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab
Arecor Therapeutics plc, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces a formulation development collaboration with Skye Bioscience, a clinical-stage biotechnology company focused on obesity and other metabolic health disorders. ...
£1 billion BioNTech investment sets way for jobs, growth, breakthroughs
Covid-19 vaccine pioneers BioNTech commit to up to £1 billion, 10-year investment in the UK. ...
Maxion Therapeutics doubles R&D space at Unity Campus after £58 million Series A fundraise
Cambridge - Leading regional property investor and developer Howard Group, is delighted to announce that pioneering biotechnology company Maxion Therapeutics has more than doubled its footprint at Unity Campus. ...